Resonea
Resonea, Inc. was a Scottsdale-based healthcare technology company that developed smartphone-based home sleep apnea diagnostic tools using acoustic flow analysis and microphone data channels. Its core diagnostic technology was acquired by EnsoData in July 2024.
- Company typePrivate
- Founded2022
- HeadquartersScottsdale, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Resonea does
Resonea, Inc. was a Delaware-incorporated, Scottsdale-headquartered healthcare technology company that developed sleep testing diagnostic technology aimed at accelerating the diagnosis of sleep disorders, particularly sleep apnea. The company's core offering centered on acoustic flow analysis and microphone data channels that enabled smartphone-based home sleep testing, positioning it to address the widespread underdiagnosis of sleep apnea through a consumer-accessible diagnostic format. The technology leveraged the ubiquity of smartphone microphones to capture respiratory acoustic signatures, eliminating the need for traditional in-lab polysomnography or dedicated hardware for initial screening.
The company operated from approximately 2016 to mid-2024, raising approximately $9.65 million across multiple funding rounds including an initial $4 million round in October 2016, a $250,000 Arizona Commerce Authority grant in January 2018, a $30,000 Flinn Foundation grant in February 2020, a $2.37 million round in September 2020, and a $5 million exempt offering (with $3 million sold) filed via SEC Form D in January 2022. The company was led by CEO Ruchir Sehra and Joe Cooper as Chief of Strategy and Corporate Development, operating with a team of 11-50 employees. Resonea held a US-only operating geography based on its Delaware incorporation and Scottsdale base.
In July 2024, Resonea's sleep testing diagnostic technology — including its acoustic flow analysis and smartphone-based home sleep testing capabilities — was acquired by EnsoData, a US-based healthcare technology and software firm. The transaction represented a technology/asset acquisition rather than an entity acquisition, and the company's website domain subsequently appears to have been repurposed, indicating that Resonea ceased independent operations following the divestiture of its core technology assets to EnsoData.
Resonea firmographics
Firmographics- Name
- Resonea
- Legal name
- Resonea, Inc.
- Website
- https://resonea.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Resonea, Inc. was a Scottsdale-based healthcare technology company that developed smartphone-based home sleep apnea diagnostic tools using acoustic flow analysis and microphone data channels. Its core diagnostic technology was acquired by EnsoData in July 2024.
- Ownership category
- akta.pro rank
Resonea industry classification
Industry- Product category
- Sleep Diagnostics Software
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy) (HLAHAGAB)
- akta.pro secondary industry
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
Keywords
Where Resonea is headquartered
LocationHeadquarters
- HQ city
- Scottsdale
- HQ country
- United States
- HQ region
- North America
Markets served
Resonea business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations
Resonea product offering
Product offeringCore offering
Resonea developed sleep testing diagnostic technology that enabled home-based sleep apnea screening using acoustic flow analysis and microphone data channels captured via smartphones. The technology was designed to accelerate the diagnosis of sleep disorders and address the widespread underdiagnosis of sleep apnea through accessible, smartphone-enabled home testing rather than traditional in-lab polysomnography.
Product overview
Resonea was a healthcare technology company that developed sleep testing diagnostic technology for sleep apnea screening. The company's primary offering was sleep testing diagnostic technology that utilized acoustic flow and microphone data channels to enable smartphone-based home sleep testing. In July 2024, Resonea's sleep testing technology was acquired by EnsoData, indicating Resonea no longer operates independently in this space.
Differentiator
Problem solved
Functional benefit
Products and services
- Sleep Testing Diagnostic Technology
Companies that use Resonea
Customer profileIdeal customer profiles2 records
Resonea technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Resonea partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- EnsoDatanotableEnsoData, a US-based healthcare technology and software firm, acquired Resonea's sleep testing diagnostic technology in July 2024. The acquisition was intended to enhance EnsoData's sleep apnea screening methods and home sleep testing capabilities through acoustic flow and microphone data channels.
Scale indicators1 record
Recent moves4 records
Expansion highlights2 records
Resonea competitors and assessment
Company assessmentBroad incumbents
- ResMed: Dominant incumbent in sleep-disordered breathing with CPAP devices, masks, and the myAir platform; an adjacent peer because it influences the diagnostic-to-therapy pathway that any HST technology must integrate with.
- Philips Sleep & Respiratory Care: Large incumbent offering CPAP, home sleep testing (Alice line), and connected sleep health platforms, providing a broad competitive backdrop for any home-based sleep apnea screening technology.
Direct peers
- EnsoData: AI-based sleep scoring and diagnostics platform that directly acquired Resonea's acoustic flow technology in 2024 to enhance its home sleep testing offering. Most direct comparable given the asset transfer and overlapping product category.
- Compumedics: Global sleep diagnostics company offering PSG and home sleep testing systems used in clinical sleep medicine; comparable in product category and end customers.
- Nox Medical: Manufacturer of the Nox T3 and other home sleep testing/recording systems used by sleep labs and clinicians, making it a direct peer in ambulatory sleep diagnostics hardware.
- Itamar Medical: Maker of the WatchPAT home sleep apnea testing device. Direct competitor in the home-based sleep apnea diagnostic category with established clinical evidence and regulatory clearances.
- CleveMed: Provides home sleep testing devices and cloud-based sleep diagnostics services for clinicians, directly competing with Resonea's home-based sleep apnea screening offering.
Emerging players
- Oura: Smart ring maker whose Oura Ring tracks sleep patterns and has begun exploring chronic condition features; represents the consumer wearable axis that could pressure smartphone-based screening.
- Withings: Consumer health hardware maker (Sleep Analyzer, ScanWatch) that has moved into home sleep apnea detection, partially overlapping with Resonea's consumer-grade, smartphone-adjacent screening approach.
- Dreem: Sleep technology company developing EEG-based headbands and digital sleep diagnostics, with overlap in home-based sleep measurement and analytics.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Resonea social profiles
Digital presenceResonea financial estimates
Financial estimateRevenue estimate
Valuation estimate
Resonea leadership team
Management profileNumber of profiles
Profiles2 records
Resonea funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Resonea M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Resonea
What does Resonea do?
Resonea developed sleep testing diagnostic technology that enabled home-based sleep apnea screening using acoustic flow analysis and microphone data channels captured via smartphones. The technology was designed to accelerate the diagnosis of sleep disorders and address the widespread underdiagnosis of sleep apnea through accessible, smartphone-enabled home testing rather than traditional in-lab polysomnography.
Is Resonea a public or private company?
Resonea is a private company. It is classified as venture growth investor backed and is currently acquired.
When was Resonea founded?
Resonea was founded in 2022. It employs 11 to 50 people.
Where is Resonea based?
Resonea is headquartered in Scottsdale, United States, in the North America region.
Who are Resonea's main competitors?
Broad incumbents on record are ResMed and Philips Sleep & Respiratory Care. Direct peers are EnsoData, Compumedics, Nox Medical, Itamar Medical and CleveMed. Emerging players are Oura, Withings and Dreem.
Does Resonea have an API?
No public API is recorded for Resonea.
What industry is Resonea in?
Resonea's product category is Sleep Diagnostics Software. Its primary akta.pro industry code is HLAHAGAB, Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy), with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its SIC code is 7372.